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Impurities can be closely related to the product that is formed during the synthesis
of a bulk drug or it can be decomposition product formed during the storage of the
drug. The International Conference on Harmonization (ICH) has published guidelines
on impurities in new drug substances, products and residual solvents. According to ICH
guidelines, an impurity should not exceed 0.1 % and total impurity should not exceed
1.0 % in manufacturing each batch of the drug (1, 2). Impurities present in excess of 0.1 %
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lam were proposed. In the present work, synthesis of these
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should be identified and quantified by sufficiently selective methods. The process of
identification and quantification of impurities is known as impurity profiling. The pro-
cedure of impurity profiling begins with the detection of impurities using thin layer
chromatography, high-performance liquid chromatography or gas chromatography (3).
The presence of impurities in bulk drug can be identified by using the impurity refer-
ence standard, which includes the products of predictable side reactions or degradation
products (4). If the retention time of both (impurities present in the bulk drug and impu-
rity reference standard) match, then the impurities present will be easily identified. In
case of unsuccessful identification, an analytical method, either LC/MS or GC/MS, is
used. Based on MS information, the structure of the impurity will be proposed. The im-
portant step in impurity profiling is the synthesis of the material (impurity standard)
with the proposed structure. Retention and spectral matching of the synthesized mate-
rial with the impurity present in the bulk drug are useful for the analytical method de-
velopment and validation. It is essential to know the structure of impurities present in
the bulk drug in order to alter the reaction conditions and to reduce the quantity of im-
purity to an acceptable level.
Midazolam is 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo [1,5-a][1,4]-benzo-
diazepine. It is used as a powerful anxiolytic, hypnotic, anticonvulsant, skeletal muscle
relaxant and sedative agent (5–8). In the manufacture of the bulk drug midazolam, eight
new impurities were proposed, which can arise due to side reactions or can be related or
degradation products.
Literature survey revealed various HPLC methods for determination of midazolam
and its metabolites in biological fluids (9–13). Based on the literature survey, an attempt
was made to synthesize the proposed impurities of midazolam and to use a RP-HPLC
method for separation of these eight impurities from the bulk drug midazolam.
EXPERIMENTAL
Apparatus and instruments
All melting points are uncorrected and were measured using a Büchi Digital auto
melting point apparatus (Büchi Corporation, Japan). IR spectra were recorded as potas-
sium bromide pellets on a Shimadzu-FTIR 8400S spectrophotometer (Japan). 1H NMR
was obtained with a Bruker Spectrospin-200 NMR spectrometer (Bruker, Germany) in
CDCl3 and dimethylsulfoxide (DMSO) as solvents, using TMS as internal reference. Mass
spectra were recorded on a Shimadzu GC/MS spectrometer 210. Follow-up of the reac-
tions and purity checking of the compounds were done by TLC on silica gel-coated alumi-
num sheets. Column chromatography was carried out on silica gel (0.15–0.25 mm, column
size i.d. 4 × 90 cm) (Merck, Germany) and mixture of all impurities from the midazolam
was studied using the instrument Shimadzu alliance HPLC, Rheodyne injector.
Materials
Midazolam and 2-aminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1H-1,4-
benzodiazepine hydrochloride salt were provided Microlabs (India). Dipotassium hy-
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drogen phosphate buffer (Qualigens Fine Chemicals, India), orthophosphoric acid (Qua-
ligens Fine Chemicals, India), methanol (HPLC grade, Qualigens Fine Chemicals) and
acetonitrile (HPLC grade Qualigens Fine Chemicals) were used. All other chemicals
were of analytical grade and were purchased from S.D. Fine Chem. Ltd, India.
Syntheses
8-Chloro-6-(2-fluorophenyl)-1-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]imidazo[1,5-a]
[1,4]-benzodiazepine (IMP 1). – A mixture of 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imi-
dazo[1,5-a][1,4]-benzodiazepine (11.2 g, 0.03 mol), dichloromethane (300 mL), glacial
acetic acid (300 mL) and Zn dust (12 g, 0.18 mol) was stirred for 3 h at room temperature
(under TLC control). Inorganic material was filtered off from the reaction mixture and
washed with dichloromethane and water. The filtrate was diluted with dichloromethane
(400 mL), water (800 mL) and made alkaline with ammonia solution (25 %). The dichlo-
romethane layer was separated, dried over sodium sulphate, evaporated and the resi-
due was crystallized from hexane to give IMP 1.
8-Chloro-6-(2-fluorophenyl)-1-methyl-6H-imidazo[1,5-a][1,4]-benzodiazepine (IMP 2). – A
mixture of midazolam (15.0 g, 0.05 mol), dichloromethane (180 mL) and potassium terc-
-butoxide (6 g) was stirred using a magnetic stirrer and cooled to –30 °C. The dark mix-
ture was acidified with glacial acetic acid (30 mL) and poured into water (500 mL). Di-
chloromethane (250 mL) was added to the reaction mixture and neutralized with
sodium bicarbonate. The organic layer (dichloromethane) was collected and the aqueous
phase was extracted with dichloromethane (250 mL). The organic layers were combined
and washed with water, dried over sodium sulfate and evaporated. The residue was
chromatographed over silica gel using dichloromethane as an eluent. The fractions were
combined, evaporated and the residue was crystallized from ethyl acetate to yield the fi-
nal product.
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine-5-oxide (IMP
3). – A mixture of midazolam (15.6 g, 0.478 mol), dichloromethane (320 mL) and m-chlo-
roperbenzoic acid (19 g, 0.11 mol) was stirred for 2 hours at room temperature (under
TLC control). The reaction mixture was extracted with 1 mol L–1 HCl (450 mL). The aci-
dic layer was collected, washed with dichloromethane (100 mL), neutralized by adding
ammonia solution (25 %) and extracted with dichloromethane. The dichloromethane
layer was collected, washed with water (50 mL), dried and evaporated. The residue ob-
tained was crystallized from ethyl acetate to give the product, which was further puri-
fied by column chromatography over silica gel using dichloromethane as an eluent.
Clean fractions were combined, evaporated and the residue was crystallized from ethyl
acetate and yielded colorless crystals of compound IMP 3.
2-Aminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1H-1,4-benzodiazepine hydrochlo-
ride salt (IMP 4). – A mixture of 2-aminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-
1H-1,4-benzodiazepine dimaleate salt (50.0 g, 0.05 mol), water (100 mL) and dichloro-
methane (100 mL) was taken and stirred for 1 hour till the dimaleate salt fully dissol-
ved. The reaction mixture was neutralized using ammonia solution (25 %) and the DCM
layer was separated; the aqueous layer was extracted with dichloromethane (100 mL).
Dichloromethane layers were combined, washed with water (100 mL), dried over so-
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dium sulfate and evaporated at reduced pressure until thick oil was obtained. The oil
was dissolved in acetone (50 mL) and a mixture of conc. HCl and isopropanol (1:1) was
added till the final pH reached 2. The reaction mixture was cooled to 10 °C, the precipi-
tate obtained was filtered off and dried to give IMP 4.
N-desalkylflurazepam (IMP 5). – Step 1. A mixture of 2-amino-5-chloro-2'-fluoro ben-
zophenone (23.0 g, 0.01 mol), sodium bicarbonate (13.0 g) and dry toluene (70.0 mL) was
stirred at 45 °C. A solution of chloroacetyl chloride (24.0 mL, 0.03 mol) in toluene (10
mL) was added dropwise under constant stirring at 50–55 °C and after complete addi-
tion, the temperature was raised to 70 °C. Stirring was continued for one hour (under
TLC control). The reaction mixture was cooled and poured into ice cold water under
constant stirring. The precipitate obtained was filtered, washed with toluene, water, hex-
ane and crystallized from methanol to give the compound 2-(2-chloro acetamido)-5-
chloro-2'-fluoro benzophenone (1) as off-white crystals.
Step 2. A mixture of 2-(2-chloro acetamido)-5-chloro-2'-fluoro benzophenone (1)
(15.0 g, 0.1 mol) and ammonia solution (25 %, 3.4 mL) in methanol (23.8 mL) was re-
fluxed (under TLC control) till the completion of reaction. Methanol was removed under
vacuum and the residue was diluted with water. The residue was filtered and washed
with water and methanol. The product obtained was crystallized from methanol (deco-
lorizing carbon was added) to give IMP 5 as a white crystalline solid.
6-Chloro-2-methyl-4-(2-fluorophenyl) quinazoline (IMP 6). – Step 1. A mixture of acet-
aldehyde (23 mL) and 1.5 mol L–1 HCl (16 mL) was stirred for 1 hour at 5 °C. The above
solution was added to a mixture of 2-amino-5-chloro-2'-fluorobenzophenone (20 g, 0.09
mol), hydroxylamine sulphate (7.2 g, 0.042 mol) and ethanol (95 %, 88 mL). The reaction
mixture was stirred for 24 hours (under TLC control) and poured off into crushed ice
(300 g) and water (400 mL). The precipitate of 6-chloro-2-methyl-4-(2-fluorophenyl)-1,2-
-dihydroquinazoline 3-oxide (2) formed was filtered and dried.
Step 2. To a mixture of 6-chloro-2-methyl-4-(2-fluorophenyl)-1,2-dihydroquinazoli-
ne-3-oxide (2) (10 g, 0.07 mol) and dichloromethane (350 mL, 0.27 mol), activated man-
ganese dioxide (30 g, 0.08 mol) was added and the reaction mixture was stirred under
reflux for 3 hours (under TLC control). The reaction mixture was filtered through celite,
washed with a 50:50 (V/V) mixture of dichloromethane and methanol (300 mL). The
combined filtrates were evaporated and 6-chloro-2-methyl-4-(2-fluorophenyl) quinazo-
line 3-oxide (3) was crystallized from methanol.
Step 3. A mixture of 6-chloro-2-methyl-4-(2-fluorophenyl) quinazoline-3-oxide (3)
(10 g, 0.034 mol) and methanol (30 mL) was stirred for 1 hour at room temperature. The
reaction mixture was cooled (10 °C) and sodium borohydride (3 g, 0.043 mol) was added
slowly. Stirring was continued additionally for 24 hours (under TLC control). The reac-
tion mixture was dissolved in methanol. Methanol was removed under vacuum and wa-
ter (50 mL) was added to the residue. The reaction mixture was neutralized by adding
dilute sulphuric acid and extracted with ethyl acetate. The ethyl acetate layer was col-
lected, dried over sodium sulfate, evaporated and the solid product of 6-chloro-2-me-
thyl-4-(2-fluorophenyl) quinazoline (IMP 6) was obtained.
8-Chloro-6-(2-fluorophenyl)-3a,4,-dihydro-1-methyl-3H-imidazo[1,5-a][1,4]benzodiazepine
(IMP 7) – Step 1. 2-Aminomethyl-7-chloro-2,3-dihydro-5-(2-fluoro-phenyl)-1H-1,4-ben-
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zodiazepine dimaleate, (8.0 g, 0.03 mol) was partitioned between dichloromethane and
an aqueous ammonia solution (5 %) in a separating funnel. The dichloromethane layer
was collected and washed with water, dried over sodium sulfate and evaporated. The
residue was dissolved in pyridine (50 mL, 0.6 mol); acetic anhydride (10 mL, 0.1 mol)
was added and the mixture was heated over a steam bath for 4 hours. The reagents were
evaporated under reduced pressure and the residue was partitioned between dichloro-
methane and an aqueous sodium bicarbonate solution (10 %). The organic layer was col-
lected, dried and evaporated. Crystallization of the residue from hexane yielded the fi-
nal product 1-acetyl-2-acetylaminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1H-
-1,4-benzodiazepine (4).
Step 2. A mixture of 1-acetyl-2-acetylaminomethyl-7-chloro-2,3-dihydro-5-(2-fluoro-
phenyl)-1H-1,4-benzodiazepine (4) (5.0 g, 0.01 mol) and polyphosphoric acid (100.0 g)
was heated over a water bath (150–170 °C) for 10 minutes. The reaction mixture was
cooled, dissolved in ice water and was made alkaline with an ammonia solution (25 %).
The precipitated base was extracted with dichloromethane. The extracts were washed
with water, dried over sodium sulfate and evaporated. The residue was chromatogra-
phed over silica gel using methanol in dichloromethane as an eluent. The pure fractions
were combined, evaporated and crystallized from ether to yield the final product.
8-Chloro-6-(2-fluorophenyl)-3a,4,5,6-tetrahydro-1-methyl-3H-imidazo[1,5-a][1,4]benzodia-
zepine (IMP 8). – A mixture of 8-chloro-6-(2-fluorophenyl)-3a,4-dihydro-1-methyl-3H-
-imidazo[1,5-a][1,4]benzodiazepine (IMP 7) (11.2 g, 0.034 mol), dichloromethane (300 mL),
glacial acetic acid (300 mL) and Zn dust (12 g, 0.18 mol) was stirred for 3 h at room tem-
perature (under TLC control). The inorganic material was filtered off from the reaction
mixture and washed with dichloromethane and water. The filtrate was diluted with di-
chloromethane (400 mL), water (800 mL) and made alkaline with an ammonia solution
(25 %). The dichloromethane layer was separated, dried and crystallized from hexane to
give IMP 8.
Development of a HPLC method for the separation of the mixture of impurities
Separation of all eight impurities from the drug midazolam was performed on a col-
umn of type C8, size: l = 0.25 m, d = 4.0 mm, 30 °C. The mobile phase consisted of dipo-
tassium hydrogen phosphate buffer (pH adjusted to 3.29 using diluted orthophosphoric
acid) /acetonitrile / methanol (71.45 : 20.7 : 7.85, V/V/V). The mobile phase was filtered
through a 0.45 mm nylon membrane filter and degassed by sonication for about 15 minu-
tes prior to use. The flow rate was 1 mL min–1, and the injection volume was 20 µL.
SPD-10 AVP UV-visible detector and class VP software was used.
Preparation of midazolam/impurities solutions
Midazolam/each impurity of midazolam (IMP 1-8) was exactly weighed and dis-
solved in methanol. Volumetric flasks were sonicated for 5 minutes and the volume was
made up with methanol. The stock solution was 0.25 mg mL–1 midazolam and 0.5 mg
mL–1 impurity 1, 2, 3, 4, 5, 6, 7 and 8, respectively. From the above stock solution, 1 mL
of each impurity was pipetted out into a 25-mL volumetric flask and the volume was
made up to the mark with the standard reference solution of midazolam. The mixture
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An attempt was made to synthesize eight impurities of the bulk drug midazolam
and characterize them by physical, chemical and spectral data (Tables I and II). Mida-
zolam could be considered as the starting material for impurities 1, 2 and 3. Synthesis of
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IMP 1 68 203 C18H15ClFN3 (327.8) 6.442
IMP 2 55 181 C18H13ClFN3 (325.8) 11.258
IMP 3 50 214 C18H13ClFN3O (341.8) 9.608
IMP 4 85 255 C16H15ClFN3 (303.8) 4.442
IMP 5 70 207 C15H10ClFN2O (288.8) 40.858
IMP 6 63 142 C15H10ClFN2 (272.8) 18.867
IMP 7 80 148 C18H15ClFN3 (327.8) 13.775
































IMP 1 and 8 involved reduction of the double bond of midazolam and dihydromida-
zolam (IMP 7) respectively, when treated with zinc dust as shown in Schemes 1 and 2.
1H NMR spectrum of IMP 1 showed one singlet broad peak at 7.7 ppm due to the NH
group and a singlet for CH at higher chemical shift (5.147 ppm) because of the de-
shielding effect of C6H5-F. Both peaks arose due to the reduction of the bond between
N=C in the 1,4-benzodiazepine ring of midazolam. 1H NMR spectrum of IMP 8 showed
a singlet peak at 5.173 ppm due to CH and one more singlet broad peak at 7.8 ppm due
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Table II. Spectral data of synthesized compounds








7.7 (br, s, 1H, NH), 6.769–7.39 (m, 8H, ArH),
2.505 (s, 3H, CH3), 3.509 (d, 1H, CH2),








2.55 (s, 3H, CH3), 4.055 (s, 1H, CH),








2.584 (s, 3H, CH3), 4.9–5.08 (q, 2H, CH2),









DMSO: 3.261–3.304 (dd, 2H, CH2), 4.27–4.317
(dd, 1H, CH), 3.101–3.152 (dd, 1H, CH2),
3.947–4.029 (d, 1H, CH2), 6.9–7.8 (m, 7H, ArH),









4.361 (s, 2H, CH2), 9.758 (s, 1H, NH),







2.950 (s, 3H, CH3),







1.694 (s, 3H, CH3), 3.975–3.998 (d, 2H, CH2),
4.615–4.672 (dt, 1H, CH), 3.896–3.925
(d, 1H, CH2), 3.436–3.476 (dd, 1H, CH2),








1.727 (s, 3H, CH3), 4.006–4.033 (d, 2H, CH2),
4.649–4.706 (dt, 1H, CH), 3.931–3.960
(d, 1H, CH2), 3.469–3.510 (dd, 1H, CH2),
7.8 (br, 1H, NH), 5.173 (s, 1H, CH),
6.938–7.652 (m, 7H, ArH)
to the NH group, indicating reduction of the bond between N=C in the 1,4-benzodiaze-
pine ring of dihydromidazolam (IMP 7). Midazolam IMP 2 was synthesized by double
bond migration when midazolam was treated with potassium tertiary butoxide and di-
methyl-formamide (DMF) at –30 °C as shown in Scheme 1. Synthesis of IMP 3 was car-
ried out by oxidation of midazolam by using m-chloroperbenzoic acid and DCM as
shown in Scheme 1. Both impurities 2 and 3 were further purified by column chroma-
tography using silica gel as an adsorbent and DCM as an eluent. 1H NMR spectrum of
IMP 2 showed a singlet at 5.13 ppm for CH at higher chemical shift because of the de-
shielding effect of C6H5-F but no absorption peak for NH indicating migration of the
double bond in the 1,4-benzodiazepine ring. IR spectrum of IMP 3 showed N→O stretch-
ing at 1531.37 cm–1 indicating oxidation of the N group in the 1,4-benzodiazepine ring of
midazolam. On the other hand, alkalization of 2-aminomethyl-7-chloro-2,3-dihydro-5-
-(2-fluorophenyl)-1H-1,4-benzodiazepine dimaleate salt conversion to its hydrochloride
salt using hydrochloride in the isopropyl alcohol mixture yielded IMP 4 (Scheme 2).
Synthesis of IMP 7 occurred in two steps. The first step involved alkalization of 2-ami-
nomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1H-1,4-benzodiazepine dimaleate salt
with ammonia and when treated with acetic anhydride underwent acetylation to yield
1-acetyl-2-acetylaminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1H-1,4-benzodia-
zepine (4). The second step was cyclisation of the acetylated intermediate (4): when
heated with polyphosphoric acid it afforded IMP 7 as shown in Scheme 2. 1H NMR
spectrum of IMP 7 showed a doublet peak at 3.975–3.998 ppm supporting the methylene
protons and a doublet or triplet peak at 4.615–4.672 ppm for CH indicating that the bond
between the C=C in the imidazole moiety of midazolam was reduced. Moreover, ami-
dation of 2-amino-5-chloro-2'-fluoro benzophenone, when treated with chloroacetyl
chloride, afforded 2-(2-chloro-acetamido)-5-chloro-2'-fluoro benzophenone (1) and this
amide underwent cyclisation in the presence of ammonia in methanol to afford IMP 5
(Scheme 3). IR spectrum of IMP 5 showed N-H stretching at 3211.26 cm–1 and C=O
392
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Table III. 13C NMR Spectral data of synthesized compounds
Code 13C NMR
IMP 1
20.31 (CH3), 51.67, 63.56, 135.17, 133.27, 132.82 (5C, diazepine), 141.53, 125.37
(2C, imidazol), 147.43, 134.71, 130.21, 129.62, 128.18, 126.57, 125.84, 124.45, 120.36,
119.81 (10C, Ar-C)
IMP 2
21.43 (CH3), 57.38, 160.23, 135.46, 132.91, 132.13 (5C, diazepine), 142.31, 124.15
(2C, imidazol), 146.21, 136.37, 131.47, 128.54, 128.03, 123.72, 122.67, 122.23, 121.38,
115.27 (10C, Ar-C)
IMP 3
20.45 (CH3), 45.83, 112.31, 138.42, 135.27, 127.63 (5C, diazepine), 140.71, 123.62
(2C, imidazol), 152.32, 136.25, 133.57, 130.72, 126.48, 125.61, 125.07, 123.32, 121.40,
116.82 (10C, Ar-C)
IMP 4
37.29 (CH2), 51.47, 62.31, 146.25, 137.56, 132.84, 125.63 (5C, diazepine), 140.52,
134.37, 132.19, 129.47, 125.86, 125.26, 124.65, 123.78, 119.54, 118.32 (10C, Ar-C)
IMP 5
56.24, 154.38, 135.42, 130.12 (4C, diazepine), 145.35, 133.28, 130.45, 128.72, 125.54,
124.36, 124.01, 122.63, 120.46, 117.29 (10C, Ar-C), 173.41 (C=O)
IMP 6
25.31 (CH3), 114.33, 116.74, 121.37, 123.32, 124.38, 125.43,126.56, 129.57, 130.68,
133.45, 135.27, 136.73, 137.24, 140.35 (14C, Ar-C)
IMP 7
24.45 (CH3), 47.62, 156.28 (2C, imidazole), 54.23, 60.45, 155.48, 140.31, 128.65
(5C, diazepine), 150.27, 132.45, 130.53, 129.63, 126.56, 123.45, 121.36, 120.72,
118.25,116.48 (10C, Ar-C)
IMP 8
24.57 (CH3), 50.23, 158.35 (2C, imidazole), 51.32, 54.26, 62.01, 140.57, 135.41
(5C, diazepine), 152.45, 134.25, 132.62, 130.58, 128.35, 126.41, 123.29, 121.87, 117.23,
115.93 (10C, Ar-C)
stretching at 1685.67 cm–1. 1H NMR showed a singlet at 4.361 ppm supporting the meth-
ylene groups and a singlet at 9.758 ppm indicating the NH group. Preparation of IMP 6
involved three steps. The first step was cyclisation as well as oxidation of 2-amino-5-
-chloro-2'-fluoro benzophenone when treated with acetaldehyde and hydroxyl amine
sulphate to yield the dihydroquinazoline-3-oxide (2). The second step was dehydroge-
nation (2) when treated with activated manganese oxide to get quinazoline-3-oxide (3).
The third step involved reduction (3) in the presence of sodium borohydride to yield
IMP 6 as shown in Scheme 3. 1H NMR of IMP 6 showed a singlet at 2.950 ppm sup-
porting the methyl protons and multiplet at 7.126–7.92 ppm indicating 7H of aromatic
moiety.
The synthesized impurities (IMP1-IMP8) were structurally elucidated on the basis
of spectral data and explained with the example of compound IMP1. The mass spec-
trum shows the presence of the peak at m/z 327.2 for M+ in accordance with the molecu-
lar formula, C18H15ClFN3. It also shows the (M+ + 2) peak at m/z 329.2 due to the pres-
ence of halogen atoms. The structures were also supported by 13C NMR data. The 13C
NMR of IMP1 showed peaks at 20.31 (CH3), 51.67, 63.56, 135.17, 133.27, 132.82 (5C,
diazepine), 141.53, 125.37 (2C, imidazole), 147.43, 134.71, 130.21, 129.62, 128.18, 126.57,
125.84, 124.45, 120.36 and 19.81 (10C, Ar-C) to confirm its structure. The other impurities
were identified in a similar manner. In IMP 4, 5 and 6, 13C NMR showed no peaks for
carbons of the imidazole ring, showing the absence of imidazole ring. 13C NMR of IMP
5 showed the peak at 173.41 for the presence of C=O group. In IMP 6 the total 14 carbon
peaks showed the presence of the quinazoline ring along with the phenyl ring.
RP-HPLC method. – Several mobile phase compositions were assayed for the separa-
tion of impurities from midazolam. Satisfactory separation of midazolam and all its
eight impurities was obtained with mobile phase consisting of dipotassium hydrogen
phosphate buffer (pH adjusted to 3.29 using dilute ortho phosphoric acid)/acetonitrile/
methanol (71.45 : 20.7 : 7.85, V/V/V). Chromatogram of the impurities mixture is shown
in Fig. 1.
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Fig. 1. Separation of mixture of impurities of midazolam. The first peak is of solvent methanol.
Parameters including the retention time, area, area midazolam resolution, capacity
factor, separation factor, asymmetry factor, HETP and number of theoretical plates are
listed in Table IV. Individual chromatogram of each impurity was also taken. The reten-
tion time of individual impurities is given in Table I.
CONCLUSIONS
The eight impurities that can be present along with the bulk drug midazolam were
synthesized. A RP-HPLC method was developed for separation of a mixture of eight im-
purities from the bulk drug midazolam HPLC. The result showed satisfactory separa-
tion of impurities, except for IMP 1 and 8 which were not separated properly. The work
is in progress to develop and validate a more selective method for the separation of all
impurities with good resolution.
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